Mechanistic study of platelet-derived exosome-mediated miR-320a on attenuation of Schizophrenia-Like Behavior in rat models via ITGβ modulation
Quick Facts
- Publication title: Mechanistic study of platelet-derived exosome-mediated miR-320a on attenuation of Schizophrenia-Like Behavior in rat models via ITGβ modulation
- Journal: Behav Brain Res
- Year: 2025
- DOI: 10.1016/j.bbr.2025.115917
- PMID/PMCID: 41202989
Research overview
This study aimed to investigate the potential of platelet-derived exosomes as a drug delivery vehicle for miR-320a to alleviate schizophrenia-like behavioral manifestations. The findings of this study offer a novel perspective on the treatment of schizophrenia and suggest that P-exos-miR-320a may represent a promising therapeutic strategy, though further validation is needed.
Key findings
Our findings indicated that treatment with platelet exosomes delivering miR-320 significantly improved the anxiety behavior and cognitive function of the rats with the schizophrenia model.
The results showed that platelet exosomes loaded with miR-320a could significantly downregulate the expression of ITGβ, and LC-MS analysis indicated a decreasing trend in serotonin (5-HT).
Study design
Platelet-derived exosomes were loaded with miR-320a via electroporation.
Schizophrenia model rats were established using MK-801.
The behavioral changes in the rats were assessed using the Morris water maze test and the open field test.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification.
Related platforms: Exoomics®
Related services and capabilities: EV Re-purification / Free-Dye Removal
References
Original publication: Mechanistic study of platelet-derived exosome-mediated miR-320a on attenuation of Schizophrenia-Like Behavior in rat models via ITGβ modulation Behavioural brain research. 2025. DOI: 10.1016/j.bbr.2025.115917. PMID/PMCID: 41202989.